Muscarinic receptors in the ocular surface

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 5, 2006, Pages 379-382

  Enríquez De Salamanca, Amalia ^a   Calonge, Margarita ^a,b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Conjunctiva; Eye; Muscarinic; Neurogenic inflammation

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR;

CONJUNCTIVA EPITHELIUM; EPITHELIUM CELL; EYE DISEASE; HUMAN; LACRIMAL GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STROMA; UPREGULATION; VERNAL CONJUNCTIVITIS;

ANIMALS; EYE DISEASES; HUMANS; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; RECEPTORS, MUSCARINIC;

EID: 33748542275     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000244800.71851.0c     Document Type: Review

References (33)

1. Nietgen GW, Schmidt J, Hesse L, et al. Muscarinic receptor functionating and distribution in the eye: molecular basis and implications for clinical diagnosis and therapy. Eye 1999; 13:285-300.
2. Duncan G, Collison DJ. Role of the nonneural cholinergic system in the eye. A review. Life Sci 2003; 72:2013-2018.
3. Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989; 12:148-151.
4. Dartt DA, Kanno H, Rios J, Zoukhri D. Role of mitogen-activated protein kinase in cholinergic stimulation of conjunctival goblet cell secretion. Adv Exp Med Biol 2002; 506:297-300.
5. Budd DC, John Chaliss RA, Young KW, Tobin AB. Cross talk between M3-muscarinic and β2-adrenergic receptors at the level of receptor phosphorylation and desensitization. Mol Pharmacol 1999; 56:813-823.
6. Wiederholt M, Shafer R, Wagner U, LeppleWienhues A. Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agentas. Ger J Ophthalmol 1996; 5:146-153.
7. Ellis DZ, Nathanson JA, Rabe J, Sweadner KJ. Carbacol and nitric oxide inhibition of NA K-ATPase activity in bovine ciliary processes. Invest Opthalmol Visual Sci 2001; 42:2625-2631.
8. Yamashita M, Fukuda Y. Incurvation of early embryonic neural retina by acetilcholine through muscarinic receptors. Neurosci Lett 1993; 163:215-218.
9. 2+ mobilisations in the neural retina of early embryonic chick. Int J Dev Neurosci 1996; 14:691-699.
10. Lind GJ, Chew SJ, Marzani D, Wallman J. Muscarinic acetylcholine receptor antagonist inhibit chick scleral chondrocytes. Invest Ophthalmol Vis Sci 1998; 39:2217-2231.
11. Lind GJ, Cavanagh HD. Identification and subcellular distribution of muscarinic acetylcholine receptor-related proteins in rabbit cornea and chinese hamster ovaries. Invest Ophthalmol Vis Sci 1995; 36:1492-1507.
12. Walkenbach RJ, Ye GS. Muscarinic receptors and their regulation of cyclic GMP in corneal endothelial cells. Invest Ophthalmol Vis Sci 1990; 31:702-707.
13. Ríos JD, Zoukhri D, Rawe IM, et al. Immnunolocalization of muscarinic and VIP receptor subtypes and their role in stimulating goblet cell secretion. Invest Ophthalmol Vis Sci 1999; 40:1102-1111.
14. Kessler TL, Mercer HJ, Zieske JD, et al. Stimulation of goblet cell mucous secretion by activation of nerves in rat conjunctiva. Curr Eye Res 1995; 14:985-992.
15. Ríos JD, Forde K, Diebold Y, et al. Development of conjunctival goblet cells and their neuroreceptor subtype expression. Invest Ophthalmol Vis Sci 2000; 41:2127-2137.
16. Dartt DA. Regulation of mucin and fluid secretion by conjunctival epithelial cells. Prog Retin Eye Res 2002; 21:555-576.
17. Jummblat JE, Jumblat MM. Detection and quantification of conjunctival mucins. Adv Exp Med Biol 1998; 438:239-246.
18. Diebold Y, Ríos JD, Rawe MI, Dart DA. Presence of nerves and their receptors in mouse and human conjunctival goblet cells. Invest Ophthalmol Vis Sci 2001; 42:2270-2282.
19. Dartt DA, Kessler TL, Chung EH, Zieske JD. Vasoactive intestinal peptide-stimulated glycoconjugate secretion from conjunctival goblet cells. Exp Eye Res 1996; 63:27-34.
20. Enríquez de Salamanca A, Siemasko KF, Diebold Y, et al. Expression of muscarinic and adrenergic receptors in the normal human conjunctival epithelium. Invest Ophthalmol Vis Sci 2005; 46:504-513. This article describes the presence of muscarinic and adrenergic receptor subtypes in the IOBA-NHC human conjunctival epithelial cell line, and the modulation of their expression under proinflammatory conditions. Alteration in several neuroreceptors expression is found under in-vitro inflammatory conditions, adding further support for a neurogenic mediation in some inflammation-mediated diseases.
21. Motterle L, Diebold Y, Enríquez de Salamanca A, Sáez V, et al. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. Arch Ophthalmol 2006; 124:462-468. The expression of several neurotransmitter receptors and neuromediators is studied in conjunctival biopsies of VKC patients and it is found to be altered both in the epithelium and stroma. This alteration may be correlated to the altered mucus expression observed in those patients. Pharmacological approaches that regulate expression and/or receptors and neuromediators may have therapeutic value.
22. Evans CM, Belmonte KE, Costello RW, et al. Substance P-induced airway hyperreactivity is mediated by neuronal M2 receptor dysfunction. Am J Physiol Lung Cell Mol Physiol 2000; 279:L477-L486.
23. Grueb M, Reinthal E, Rohrbach JM, Bartz-Schmidt KU. Muscarinic acetylcholine receptor subtypes in human corneal epithelium and endothelium. Graefe's Arch Clin Exp Ophthalmol 2006; Epub ahead of print. The specific muscarinic subtype expression in human corneal epithelium and endothelium are studied by immunohistochemistry, immunofluorescence and western blot.
24. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998; 17:584-589.
25. Kovacs L, Torok T, Bari F, et al. Impaired microvascular response to cholinergic stimuli in primary Sjogren's syndrome. Ann Rheum Dis 2000; 59:48-53.
26. Bacman S, Perez Leiros C, Sterin-Borda L, et al. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren's syndrome. Invest Ophthalmol Vis Sci 1998; 39:151-156.
27. Humphreys-Beher MG, Peck AB. New concepts for the development of autoimmune exorinopathy derived from studies with the NOD mouse model. Arch Oral Biol 1999; 44:S21-S215.
28. da Costa SR, Wu K, MacVeigh M, et al. Male NOD mouse external lacrimal glands exhibit profound changes in the exocytotic pathway early in postnatal development. Exp Eye Res 2006; 82:33-45. This paper describes the changes in M3-muscarinic receptor expression and altered secretory vesicles that are found in NOD mice lacrimal gland, corroborating previous findings about M3-muscarinic receptor implication in Sjögren's syndrome patients.
29. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 2004; 138:6-17.
30. Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular complications of Sjogren's syndrome. Curr Allergy Asthma Rep 2005; 5:327-332. The use of muscarinic agonists pilocarpine and cevimeline for the treatment of ocular complications of Sjögren's syndrome, among other substances, is discussed and revised.
31. Cha S, Singson E, Cornelius J, et al. Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjogren's syndrome-associated autoantibodies. J Rheumatol 2006; 33:296-306. The authors investigate whether chronic stimulation of the M3-muscarinic receptor by anti-M3-receptor autoantibodies and/or pilocarpine resuts in a general M3-muscarinic receptor densitization.
32. Aragona P, Di Pietro R, Spinella R, Mobrici M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren's syndrome. Br J Ophthalmol 2006; 90:166-170. In this study the authors evaluate oral pilocarpine treatment on conjunctival epithelium of patients with Sjögren's syndrome, showing an increase in goblet cell number and an amelioration of conjunctival epithelium.
33. i mobility.